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Background: Tumor cell subpopulations can either compete with each other for nutrients and physical space
within the tumor niche, or co-operate for enhanced survival, or replicative or metastatic capacities. Recently, we
have described co-operative interactions between two clonal subpopulations derived from the PC-3 prostate cancer
cell line, in which the invasiveness of a cancer stem cell (CSC)-enriched subpopulation (PC-3M, or M) is enhanced
by a non-CSC subpopulation (PC-3S, or S), resulting in their accelerated metastatic dissemination.
Methods: M and S secretomes were compared by SILAC (Stable Isotope Labeling by Aminoacids in Cell Culture).
Invasive potential in vitro of M cells was analyzed by Transwell-Matrigel assays. M cells were co-injected with S cells
in the dorsal prostate of immunodeficient mice and monitored by bioluminescence for tumor growth and
metastatic dissemination. SPARC levels were determined by immunohistochemistry and real-time RT-PCR in tumors
and by ELISA in plasma from patients with metastatic or non-metastatic prostate cancer.
Results: Comparative secretome analysis yielded 213 proteins differentially secreted between M and S cells. Of
these, the protein most abundantly secreted in S relative to M cells was SPARC. Immunodepletion of SPARC
inhibited the enhanced invasiveness of M induced by S conditioned medium. Knock down of SPARC in S cells
abrogated the capacity of its conditioned medium to enhance the in vitro invasiveness of M cells and
compromised their potential to boost the metastatic behavior of M cells in vivo. In most primary human prostate
cancer samples, SPARC was expressed in the epithelial tumoral compartment of metastatic cases.
Conclusions: The matricellular protein SPARC, secreted by a prostate cancer clonal tumor cell subpopulation
displaying non-CSC properties, is a critical mediator of paracrine effects exerted on a distinct tumor cell subpopulation
enriched in CSC. This paracrine interaction results in an enhanced metastatic behavior of the CSC-enriched tumor
subpopulation. SPARC is expressed in the neoplastic cells of primary prostate cancer samples from metastatic cases,
and could thus constitute a tumor progression biomarker and a therapeutic target in advanced prostate cancer.
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The progression from normal tissue to a malignant tumor
is driven by the acquisition of genetic and epigenetic
changes together with a selection of the cells with an advan-
tage in proliferation and survival [1]. Tumor microenviron-
ments, composed by non-neoplastic cells, can also induce
transcriptional reprogramming in neoplastic cells by the
secretion of factors like TGF-β and PDGF [2], hormones or
hypoxic stress [3]. The final outcome is the coexistence in a
given tumor of phenotypically different subpopulations or
subclones of tumor cells (intratumoral heterogeneity).
Neoplastic cell subpopulations can interact with non-
neoplastic elements of the tumor microenvironment and
use them for their advantage [4]. In addition, different cell
subpopulations within a tumor can interact with each
other as in any ecological niche [5], either by competing
for common resources [6] or by cooperating for mutual
benefit [7,8]. In this context, interclonal cooperativity can
occur, defined as the state in which two or more neoplastic
clones display a more malignant phenotype in coexistence
than in isolation [9,10]. Thus, two neoplastic clones - of
which one, or both, is not intrinsically invasive and/or
metastatic- can interact when they are in proximity to one
another in order to become invasive and metastatic.
In a previous study [11], we have characterized clonal
subpopulations derived from the PC-3 prostate cancer
cell line in which one subpopulation displayed features
suggestive of enrichment for CSCs, including high tumori-
genic and metastatic potentials, and a second subpopula-
tion was depleted of CSCs and was poorly tumorigenic
and metastatic (non-CSC subpopulation). In this model,
the CSC-enriched subpopulation shows a strong epithelial
phenotype, while, in contrast, the non-CSC subpopulation
shows a strong and stable mesenchymal phenotype. We
found that the non-CSC subpopulation enhanced the
metastatic potential of the CSC-enriched subpopulation
[11], thus providing experimental support to the hypoth-
esis of cooperative interactions among CSC and non-CSC
tumor cell subpopulations displaying distinct phenotypes
[7,12] with the result of enhanced metastatic dissemin-
ation of the overall tumor. Our preliminary evidence also
suggested that such cooperation was at least partially me-
diated by diffusible factors in our cellular models [11].
Here we report that the matricellular protein SPARC is
the major diffusible factor produced by the PC-3S non-
CSC clonal subpopulation that mediates the enhanced in-
vasiveness and metastatic dissemination of the CSC-rich
PC-3M subpopulation of the PC-3 prostate cancer cell line.
Results
Neoplastic non-CSC cells enhance the invasiveness of
CSC-enriched prostate cancer cells
M and S clonal cell subpopulations were derived from the
parental PC-3 prostate cancer cell line [11]. M cells exhibitan epithelial phenotype characterized by cobble-like mono-
layer growth and the expression of epithelial markers,
whereas S cells present a strong mesenchymal pheno-
type with fibroblast-like morphology and the expression
of mesenchymal markers. They also differ in their ability
for anchorage-independent growth and invasiveness.
Thus, M but not S cells readily form spheroids in in vitro
3D cultures, a surrogate indicator of self-renewal potential
(Figure 1a). In contrast, S cells exhibit remarkable inva-
siveness in Transwell-Matrigel assays compared to M cells
(Figure 1b).
To determine if the highly invasive S cells can modulate
the invasive potential of poorly invasive M cells, we ana-
lyzed the invasiveness of M cells alone and after co-culture
with S cells. M cells were labeled with Oregon Green 488
carboxy-DFFDA-SE, S cells were labeled with Far Red
DDAO-SE, and the two cell lines were seeded in the upper
chamber of Transwell-Matrigel units. After 24 h, cells that
had invaded to the lower chamber were analyzed by flow
cytometry. The results indicated that M cells are signifi-
cantly enhanced in their invasiveness after co-culture with
S cells (Figure 1c and Additional file 1: Figure S1). To dis-
tinguish whether the observed effect could be explained by
cell-to-cell contact or by diffusible factors, we prepared S-
conditioned medium (S-CM) under serum-free growth
conditions. As can be seen (Figure 1d), S-CM strongly
stimulated the invasiveness of M cells, without major ef-
fects on their growth rate (Additional file 1: Figure S2), in-
dicating that diffusible factors secreted by S cells enhance
the invasive behavior of M cells.
The incubation of M cells with S conditioned medium
caused an induction of the transcript levels of SNAI2
and SNAI1 (Figure 1e) and an upregulation of fibronectin
accompanied with a modest downregulation of E-cadherin
protein levels (Figure 1f), suggestive of an epithelial-
mesenchymal transition, which provides a mechanistic ex-
planation for the enhanced invasiveness observed in M
cells. We next explored the relevance of cell signaling cas-
cades in this activity. For this, we treated M cells with S-
CM, without (control) or with the addition of inhibitors of
selected signaling pathways. Several inhibitors caused 50%
or more inhibition of M cell invasiveness induced by S-
CM, including the phosphoinositide 3-kinase inhibitors
LY294002 and wortmannin, the MAP kinase inhibitor
PD98059, the IKK-β inhibitor sc-514, and the Src tyrosine
kinase inhibitor PP1 (Figure 1g and Additional file 1: Table
S1). Thus, active PI3K, MAPK, NF-κB and tyrosine kin-
ase pathways are required for an optimal invasive re-
sponse by M cells to S-CM.
SPARC is the extracellular protein most abundantly
secreted by S cells vs. M cells
We used SILAC for an unbiased identification of compo-
nents of S-CM potentially responsible for the enhanced
Figure 1 Conditioned medium from S cells strongly enhance the invasiveness of M cells. (a) M cells, but not S cells, display a strong
potential for anchorage-independent growth. Spheroid assays were performed in triplicates and values shown are mean ± SD. (b) S, but not M
cells, display a strong intrinsic invasive potential in Transwell-Matrigel assays. (c) Co-culture with S cells strongly enhances the invasiveness of M
cells. Oregon Green 488-labeled M cells were co-cultured for 24 h with Far Red-DDAO-SE-labeled S, placed on Transwell-Matrigel chambers and
invasive cells in the lower chamber scored and assigned cell of origin according to their fluorescence. (d) Conditioned medium from S (S-CM)
cells strongly enhances the invasiveness of M cells. M cells were treated with control or S-CM and assayed for invasiveness. (e) Treatment of M
cells for 48 h with S-CM induces the expression of EMT-genes SNAI1, SNAI2, ZEB 1 and TWIST1. Transcript levels for different genes were quantified
by real-time RT-PCR. RPL18 (S18) levels were used as internal references and the ΔΔCt method applied to normalize against values determined
for M cells treated with CD-CHO control medium (f) Treatment of M cells with S-CM induces upregulation of FN1 and downregulation of CDH1.
Western blotting experiments with lysates from PC-3M cells treated with S-CM for 24 or 48 h. (g) Several signaling pathways are required for the
enhanced invasiveness of M cells stimulated by S-CM. M cells were treated with S-CM medium without (control) or with different inhibitors (working
concentrations of inhibitors are listed in Additional file 1: Table S1) and assayed for invasiveness. Asterisks: p ≤0.001 compared to control. Experiments
(b) to (e) were performed in quadruplicates or triplicates and the data shown are percentages of invasiveness relative to control ± SD. Asterisks denote
statistically significant differences (two-tailed Student’s t-test).
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http://www.molecular-cancer.com/content/13/1/237invasiveness of M cells (Figure 2a). S cells were metabolic-
ally labeled with “heavy” forms of L-lysine and L-arginine
(13C6-L-lysine and
13C6-L-arginine), whereas M cells con-
tained the “light” forms of the same amino acids. Condi-
tioned media from both cell lines were mixed at a 1:1
ratio, subjected to SDS-PAGE, silver stained, eluted,
digested, peptides identified by mass spectrometry and
their relative levels determined as the ratio between
“heavy” vs. “light” peptides (Additional file 2: Table S2).
We considered the proteins identified with a heavy/light
(H/L) ≥2 ratio as differentially secreted by S cells (over-
represented in S cells), whereas proteins with a H/L ≤ −2
ratio were considered as secreted predominantly by M
cells (under-represented in S cells). Putative subcellular lo-
calizations of the identified proteins were assigned with
the aid of the Gene Ontology and UniProtKB databases
(Figure 2b). Several proteins are assigned more than one
subcellular compartment, which explains that the sum of
all compartments may exceed 100%. As described for
other cellular secretomes [13-15], the majority of the pro-
teins identified in the conditioned media from both M
and S cells were assigned a cytoplasmic localization, andFigure 2 SPARC is the secreted protein most abundantly produced b
used to identify the proteins present in M-CM and S-CM using SILAC labeli
for the differentially secreted proteins. (c) Gene Ontology biological proces
with H/L ≥2. S < M: proteins with H/L≤ −2. (d) Western blotting analysis of
of SPARC and PAI-1 between S and M cells. Tubulin signal was used as a prote
conditioned medium.only about 20% of the proteins were predicted extracellu-
lar or secreted status. Cytoskeletal proteins were more
abundant in M-CM than in S-CM, whereas lysosomal
proteins were more abundant in the latter (Figure 2b).
Gene Ontology and UniProtKB databases were also used
to functionally classify the identified proteins. The pro-
teins over-represented in S-CM are mainly involved in
apoptosis and carbohydrate, lipid and amino acid metab-
olism, whereas those over-represented in M-CM are
mainly involved in cell adhesion, cell organization and
biogenesis and response to stimulus (Figure 2c).
We reasoned that the diffusible factor or factors respon-
sible for the increased invasiveness of M cells in response
to S-CM would most likely reside within the set of canon-
ical extracellular proteins over-represented in S-CM. Of
these, SPARC ranged first, with a H/L ratio of 13.32,
followed by PAI-1 (Plasminogen Activator Inhibitor-1),
Extracellular Superoxide Dismutase, Calreticulin and
Pentraxin-3 (Table 1). These five top-scoring differentially
secreted proteins are of particular interest because they
are potential markers of cancer progression and metastasis
and some of them play roles in cell migration, woundy S cells relative to M cells. (a) Schematic depiction of the procedure
ng. (b) Gene Ontology and Uniprot subcellular localization predictions
s predictions for the differentially secreted proteins. S > M: proteins
cell extracts and conditioned medium confirms the differential expression
in loading and transfer control for cell lysates, and Ponceau red staining for
Table 1 List of extracellular proteins most significantly overrepresented in S vs. M conditioned medium
Accession Protein name H/L ratio Expression in microarrays
SPRC_HUMAN SPARC 13.32 S > M
PAI1_HUMAN Plasminogen activator inhibitor 1 = SERPINE1 12.81 S > M
SODE_HUMAN Extracellular superoxide dismutase [Cu-Zn] OS = SOD3 11.11 S > M
CALR_HUMAN Calreticulin = CALR 10.92 NOT CONCLUSIVE
PTX3_HUMAN Pentraxin-related protein PTX3 = PTX3 7.33 S > M
SODC_HUMAN Superoxide dismutase [Cu-Zn] = SOD1 5.92 S > M
ISG15_HUMAN Ubiquitin-like protein ISG15 = ISG15 4.10 S > M
PDIA1_HUMAN Protein disulfide-isomerase = P4HB 3.84 S > M
CS010_HUMAN UPF0556 protein C19orf10 = C19orf10 3.81 S > M
ERAP1_HUMAN Endoplasmic reticulum aminopeptidase 1 = ERAP1 3.61 NOT PRESENT IN MA*
CATZ_HUMAN Cathepsin Z = CTSZ 3.38 NOT CONCLUSIVE
GGH_HUMAN Gamma-glutamyl hydrolase = GGH 3.32 S > M
TCTP_HUMAN Translationally-controlled tumor protein = TPT1 2.56 S > M
PEBP1_HUMAN Phosphatidylethanolamine-bindingprotein 1 = PEBP1 2.46 M > S
AIBP_HUMAN Apolipoprotein A-I-binding protein = APOA1BP 2.23 NOT CONCLUSIVE
*MA, Microarray.
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PCR (qPCR) analysis indicated that their corresponding
mRNAs are indeed over-represented in S cells relative to
M cells, with SPARC and PAI-1 expression levels in S cells
more than ten-fold higher than in M cells (Additional
file 1: Figure S3). The abundance of these two proteins in
cell extracts and conditioned medium was also analyzed
by Western blotting, confirming that SPARC and PAI-1
are expressed and secreted at significantly higher levels by
S cells than M cells (Figure 2d). The expression levels of
SPARC in parental PC-3 cells were intermediate between
the relatively high levels in S cells and the lower levels in
M cells (Additional file 1: Figure S4). SPARC expression
levels were extremely low or undetectable in the androgen-
independent Du-145 and CWR22Rv1 (henceforth, 22Rv1)
prostate cancer cells and in the androgen-dependent
LNCaP cells (Additional file 1: Figure S4).
SPARC mediates the enhanced invasiveness of M cells
stimulated by S cells
To determine the importance of SPARC in the pro-
invasive activity of S-CM on M cells, we performed in-
vasion assays comparing M cells alone, M cells treated
with S-CM and M cells treated with S-CM that had been
depleted of SPARC using a specific antibody. Immunode-
pletion of SPARC from S-CM abrogated its ability to
enhance the invasive behavior of M cells (Figure 3a). In
parallel experiments, immunodepletion of PAI-1 from S-
CM did not significantly inhibit its ability to enhance the
invasion of M cells (Figure 3b). Furthermore, the addition
of recombinant SPARC to the culture medium enhanced
the invasive behavior of M cells (Figure 3c). Theseobservations allow us to conclude that SPARC, but not
PAI-1, is a candidate secreted factor that may explain
the pro-invasive effect of S-CM on M cells.
On the other hand, time-course experiments showed
that incubation with SPARC induced the phosphorylation
of ERK1/2 in M cells (Additional file 1: Figure S5), sug-
gesting a role for the activation of the MAPK pathway
in the observed phenotypic effects caused by SPARC,
also supported by the abrogation of S-CM-stimulated
invasiveness of M cells by MAPK inhibitors described
above (Figure 1g). Although the activation of AKT by
SPARC is less conspicuous because of the basal levels of
activation of the PI3K-AKT pathway due to the loss of
PTEN in PC-3 cells [22], the participation of this path-
way in the effects induced by SPARC in M cells is also
supported by the above experiments with pathway com-
ponent inhibitors (Figure 1g). Of interest, ILK, expressed
at low levels in M cells, was not activated in these experi-
ments (Additional file 1: Figure S5). This suggests that the
integrin-ILK pathway, shown by others to couple SPARC-
prompted signaling in other models [23-25], is not in-
volved in the invasive response of M cells to SPARC.
We next proceeded to knock down SPARC in S cells
by means of specific shRNAs, yielding S.sh8709 cells.
Knock down of SPARC was verified by qPCR and West-
ern blotting of cell extracts and conditioned medium
(Figure 4a). Conditioned medium from S.sh8709 cells
showed a reduced ability to enhance the invasiveness of
M cells as compared to control S-CM (Figure 4b). More-
over, addition of purified recombinant human SPARC to
S.sh8709 conditioned medium rescued its ability to en-
hance the invasiveness of M cells, restoring it to a pro-
Figure 3 Immunodepletion of SPARC abrogates the M pro-invasive activity of S-conditioned medium. (a) Immunodepletion of SPARC
abrogates the ability of S conditioned medium to enhance the invasiveness of M cells. Top panel: Western blots show the amount of SPARC
protein present in immunoprecipitates (IP) and supernatants (Sn) of S conditioned medium subjected to immunoprecipitation of SPARC using
2 μg/mL of anti-SPARC plus protein G (2 h incubation at 4°C). IgG plus protein G was used as a specificity control. C corresponds to control medium
and (−) corresponds to S-CM treated only with protein G beads but no specific antibodies. Bottom panel: Relative invasiveness in Transwell-Matrigel
assays of M cells treated with control medium, S-conditioned medium, and medium immunodepleted for SPARC or its IgG control. (b) Same as in
a, substituting a specific anti-SPARC antibody for anti-PAI-1. (c) Exogenous SPARC stimulates the invasiveness of M cells. Transwell-Matrigel assay
comparing the relative invasiveness of M cells under standard conditions or treated with 20 μg/mL of recombinant human SPARC protein. All
experiments were performed in quadruplicates or triplicates and the data shown are percentages of invasiveness relative to control ± SD. Asterisks
denote statistically significant differences (two-tailed Student’s t-test).
Figure 4 SPARC is a key factor mediating the pro-invasive activity of S cells on M cells. (a) Validation of SPARC knockdown in S cells. Top:
qPCR transcript quantification of SPARC in S cells transduced with SPARC-targeting (sh8709 and sh8711) or control shRNAs. RPL18 (S18) levels
were used as internal references. Values are plotted as percent transcript levels in SPARC-knockdown vs. control cells. Bottom: Western blotting
verification of SPARC knockdown by sh8709 and sh8711. Tubulin signal was used as loading and transfer reference for cell lysates, and Ponceau
red staining for conditioned medium. (b) Knock down of SPARC in S cells abrogates their conditioned medium pro-invasive activity on M cells.
Transwell-Matrigel assays compared the relative invasiveness of M cells treated with conditioned medium from S.shControl, S.sh8709 or S.sh8711
cells. (c) Recombinant SPARC restores the pro-invasive activity of conditioned medium from S.sh8709 cells. Transwell-Matrigel assays compared
the relative invasiveness of M cells treated with conditioned medium from S.shControl, S.sh8709 or S.sh8709 cells supplemented with 20 μg/mL
recombinant human (rh) SPARC. M invasiveness under rhSPARC-supplemented S.sh8709-conditioned medium was not significantly different from
that induced by control medium. (d) SPARC is required for the induction of M invasiveness by co-cultured S cells. Top: S cells integrating
doxycycline-inducible SPARC-specific shRNA (S.sh3399) were treated, or not, with 1 μg/mL doxycycline for 72 or 96 h and analyzed for SPARC
levels by Western blotting. Tubulin was used as a loading and transfer reference. Bottom: Transwell-Matrigel assay comparing the relative invasiveness
of M.GFP cells after 24 h of co-culture with control M cells or S.sh3399 cells treated, or not, with 1 μg/mL doxycycline. Invasiveness experiments in
(b), (c) and (d) were performed in triplicates or quadruplicates and shown are percentages of invasiveness relative to control ± SD. Asterisks
denote statistically significant differences (two-tailed Student’s t-test).
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(Figure 4c). Of note, knockdown of SPARC in S cells
caused a decrease in their invasiveness (Additional file 1:
Figure S6). We also tested the effect of SPARC on the
invasive potential of other prostate cancer cells, finding
that recombinant human SPARC caused an enhanced
invasiveness of the androgen-independent Du-145 and
22Rv1 cells, but not the androgen-dependent LNCaP
cells (Additional file 1: Figure S7). Taken together, these
results indicate that SPARC is the major factor respon-
sible for the enhanced invasiveness of M cells stimulated
by S-CM, and that it can stimulate the invasiveness of
other androgen-independent prostate cancer cells.
Of additional interest, knock down of SPARC in S cells
was accompanied with a decrease in PAI-1 expression at
the mRNA and protein levels (Additional file 1:
Figure S8). It has been reported that the expression of
PAI-1 is modulated by changes in the expression levels of
SPARC [26]. Therefore, although our immunodepletion
experiments suggest that PAI-1 may not play a major role
in the enhanced invasiveness of M cells by S-CM, we
cannot completely rule out the involvement of PAI-1 in
the cooperative interaction between our tumor cell sub-
populations, albeit secondary to modulation of SPARC
levels.
In order to determine the relative importance of
SPARC in the M and S cell interactions through diffus-
ible factors or direct cell-to-cell contact, we performed a
co-culture experiment, in which M cells were mixed and
cultured together, in a 1:1 proportion, with S cells bear-
ing a construct for the doxycycline-inducible expression
of a SPARC-specific shRNA (S.sh3399) (Figure 4d and
Additional file 1: Figure S9). Under control conditions, S
cells significantly enhanced the invasiveness of M cells
(Figure 4d). Importantly, doxycycline-induced SPARC
knock down abrogated the capacity of S cells to enhance
the invasive behavior of M cells (Figure 4d). These re-
sults indicate that the expression of SPARC by S cells
explains not only their ability to enhance the invasive-
ness of M cells through secreted factors, but also the
overall pro-invasive properties of S cells on M cells,
encompassing effects mediated by diffusible factors and
by putative direct cell-to-cell contact.
SPARC produced by non-CSC S cells boosts the in vivo
growth and metastatic dissemination of CSC-enriched M
cells
Our previous studies [11] had indicated that the meta-
static potential of CSC-enriched M cells is strongly
boosted by co-implantation in immunodeficient mice
together with non-CSC S cells. To determine the im-
portance of SPARC expressed by S cells in their pro-
metastatic cooperation with M cells, we proceeded to
the implantation of M cells together with S.sh3399 cellsin the dorsal prostates of male SCID-beige mice. Tumor
growth at the site of implantation and spread to distant
organs was monitored by bioluminescent imaging (BLI),
with or without doxycycline in the drinking water of mice.
Without doxycycline administration, co-implantation of
M cells and S.sh3399 cells strongly accelerated tumor
growth at the orthotopic implantation site as compared to
the growth rate of M cells alone (Figure 5a). Remarkably,
administration of doxycycline, which suppresses SPARC
expression in S.sh3399 cells (Figure 4d), significantly
inhibited the tumor-stimulating effect of S.sh3399 cells
on M cells (Figure 5b and c). In control experiments,
S.sh3399 cells alone did not grow detectable tumors or
metastases 24 days after implantation in the prostate
(Additional file 1: Figure S10), and doxycycline alone
did not inhibit the growth of M cells (Additional file 1:
Figure S11). This suggests that SPARC produced by S cells
is a major inducer of the accelerated growth of M cells
upon co-implantation with S cells in the prostate.
We next quantified the luciferase activity in the lungs
from mice with prostatic implantation of M cells, together
or not with S.sh3399 cells, with or without doxycycline ad-
ministration. Lungs were removed from euthanized mice
at day 24 of monitoring for ex vivo bioluminescence quan-
tification. It can be seen that co-implantation of M cells
with S.sh3399 cells, without doxycycline administration,
stimulated the localization in the lungs of light-emitting
tumor cells (Figure 5d). Histochemical examination con-
firmed that these lungs effectively harbored tumor cell
colonies (Additional file 1: Figure S12). Administration of
doxycycline strongly inhibited this effect (Figure 5d), in-
dicating that SPARC produced by S cells is responsible
for the enhanced metastatic spread of M cells stimu-
lated by S cells.
SPARC is expressed in the epithelial tumoral components
of metastasis-associated primary prostate tumors
Our above results suggest that expression and secretion
of high levels of SPARC by a non-CSC neoplastic cell
subpopulation promote the metastatic spread of tumor
cells with CSC traits. Conflicting reports have described
the expression levels of SPARC to be either increased or
decreased in association with advanced prostate cancer
[18,27]. We thus performed an immunohistochemical
analysis of SPARC expression in primary prostate carcin-
oma samples associated, or not, with lymph node involve-
ment (metastatic or non-metastatic primary tumors,
respectively). The specificity for SPARC of the antibody
used in these analyses was thoroughly verified in the
preceding RNAi-mediated knockdown, immunoprecipi-
tation and Western blotting experiments. This analysis
showed that SPARC was readily detectable in the stro-
mal components of all tumors, except one metastatic
case, without evident associations of percentages or
Figure 5 SPARC boosts in vivo growth and metastatic dissemination of M cells. (a) SCID-Beige mice (n =10 / experimental group) were
inoculated orthotopically (dorsal prostate) with 1x105 firefly luciferase-expressing M.Fluc and S.Fluc.sh3399 cells, as indicated, and growth monitored
by external BLI. Mice implanted with S.Fluc.sh3399 cells integrating doxycycline-inducible SPARC-specific shRNA were administered, or not, doxycycline
for the entire duration of monitoring (+dox or -dox, respectively). (b) Representative images corresponding to mice in the same experimental
groups as in (a). (c, d) Upon termination of the in vivo bioluminescent monitoring (day 24), prostates (c) and lungs (d) from inoculated animals were
removed, incubated with D-luciferin and photon counts determined. Asterisks denote statistically significant differences (two-tailed Mann–Whitney test).
Dotted lines represent non-linear fitting to the exponential growth equation Y = Y0
(kX).
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Additional file 1: Table S4). Remarkably, 14 out of 16 pri-
mary metastatic tumors, and 1 out of 14 non-metastatic
tumors analyzed, also displayed unequivocal staining for
SPARC in their epithelial tumoral components. The pro-
portion of epithelial cells that stained for SPARC varied
from 10% to 100% in different samples, ranging in inten-
sity from weak to strong, mostly with a cytoplasmic pat-
tern but also with a clear nuclear staining in 10 out of the
16 samples from metastatic cases (Figure 6a, Additional
file 1: Table S4). In spite of its predominant nuclear
localization in several metastatic cases, SPARC staining
also consistently yielded discrete dots localized in the
cytoplasm, with a perinuclear or juxtamembrane patterns
(Figure 6a). The staining for SPARC in the epithelial tu-
moral component correlated with high Gleason scores of
the samples (Additional file 1: Table S4), which agrees
with the known association of metastatic prostate cancer
with high Gleason indexes of primary tumors [28].
The observed staining for SPARC in the epithelial tu-
moral component of prostate cancer samples could be at-
tributed either to endogenous SPARC produced by tumorcells, or to stromally produced SPARC uptaken by neo-
plastic cells. Others have shown that exogenous SPARC
can be internalized by cells [29,30] and, indeed, M cells in-
cubated with S-CM as a source of SPARC show enhanced
cytoplasmic and nuclear staining for SPARC, suggesting
active uptake (Additional file 1: Figure S13). Thus, in
order to further establish the origin of the observed stain-
ing for SPARC in prostate tumor samples, real-time PCR
was performed on RNA samples isolated from laser-
microdissected epithelial or stromal components of non-
metastatic or metastatic primary tumors. The epithelial
components of tumors from the four non-metastatic cases
expressed lower levels of SPARC mRNA than the corre-
sponding stromal components (epithelial/stromal ratios of
0.16, 0.34, 0.34 and 0.40) (Figure 6b). In contrast, the epi-
thelial components of tumors from all four metastatic
cases expressed higher SPARC mRNA levels than the epi-
thelial components of non-metastatic cases, surpassing in
several cases the relative expression levels of the corre-
sponding stromal components (epithelial/stromal ratios of
0.47, 0.95, 1.29 and 1.29) (Figure 6b). This increased ex-
pression of SPARC in the epithelial tumor components of
Figure 6 (See legend on next page.)
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Figure 6 Increased expression of SPARC in the epithelial component of primary prostate cancer associated with lymph node
metastasis. (a) Immunohistochemical staining for SPARC of primary prostate cancer samples without (non-metastatic; samples i and ii) or with
(metastatic; samples iii and iv) associated lymph nodes. A discontinuous line in sample iii delimits the stromal and epithelial tumoral components.
Images are representative of stainings performed on 14 non-metastatic and 16 metastatic primary prostate cancer samples (case ID’s 28, 31, 38
and 59 from Additional file 1: Table S4). Size bar, 100 μm. (b) Real-time RT-PCR determinations of SPARC transcript levels in laser-microdissected
epithelial or stromal components of non-metastatic or metastatic primary prostate cancer samples. Values represent transcript levels inferred from
Ct values for SPARC normalized to Ct values for reference β2-microglobulin transcripts. Overall, non-microdissected transcript levels for the
corresponding samples, determined in (c), are represented next to the relative levels for the microdissected components. Data are expressed as
2-ΔCt (microdissected samples, TaqMan assays) or 2-ΔCp (non-microdissected samples, UPL assays) using β2-microglobulin or 18S ribosomal RNA
levels, respectively, as internal references. Note that value scales are different for microdissected (μd, left y-axis) or non-microdissected (non-μd,
right y-axis) samples. (c) Real-time RT-PCR determinations of SPARC transcript levels in non-metastatic (n =15) or metastatic (n =17) primary
prostate cancer samples. Data are expressed as 2-ΔCp, using 18S ribosomal RNA levels as an internal reference. No statistically significant
differences are observed in median levels for non-metastatic vs. metastatic samples. (d) Plasma SPARC levels determined by ELISA in control
individuals (n =4) and in patients with non-metastatic (n =10) or metastatic (n =14) prostate cancer. Asterisks denote statistically significant
differences in median plasma SPARC levels between patients with metastatic prostate cancer and patients with non-metastatic disease or
controls (two-tailed Mann–Whitney test).
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SPARC expression levels in the overall tumor sample, as
tumors with low overall levels exhibited high epithelial/
stromal SPARC expression ratios and tumors from non-
metastatic cases with high overall SPARC expression
levels showed low epithelial/stromal SPARC expression
ratios (Figure 6b). These observations support the en-
dogenous neoplastic cell of origin of the SPARC staining
observed in the epithelial tumoral components of primary
prostate tumors associated with metastasis, although they
do not formally rule out a stromal contribution of the
SPARC protein detected in the neoplastic cells.
In contrast to the strong concordance between epithe-
lial tumor expression of SPARC and metastatic status,
overall SPARC mRNA levels from non-microdissected
samples did not show a significant correlation with meta-
static status (Figure 6c), with the observation of a high
variability among samples, in particular in non-metastatic
cases. To determine if elevated epithelial SPARC levels in
metastasis-associated primary tumors is reflected in levels
of circulating SPARC, we quantified by ELISA the levels
of SPARC in the plasma of prostate cancer patients with
our without associated lymph node or distant metastases
that were not under systemic therapy. We found that
plasma SPARC levels in metastatic prostate cancer pa-
tients tended to be lower than those in non-metastatic
cases or control individuals (Figure 6d), and thus we
conclude that plasma levels of SPARC in prostate can-
cer patients do not reflect tumoral SPARC expression
levels.
To summarize these observations, expression of SPARC
is limited to the stroma of non-metastatic primary tumors,
whereas primary tumors from metastatic cases also ex-
press SPARC in the tumoral epithelium. Overall tumor
SPARC mRNA levels or plasma SPARC protein levels
show no significant correlation to metastatic status in
prostate cancer.Discussion
Neoplastic cellular subpopulations displaying distinct
phenotypes can interact among them in different ways
[31], including competition [6,32] or cooperation [33].
In a prostate cancer cell model previously characterized
by us [11], two subpopulations interact in a cooperative
manner, such that one subpopulation enhances the
metastatic dissemination potential of the other. In
this model, a clonal tumor cell subpopulation displays
non-CSC characteristics, including poor anchorage-
independent growth in vitro and limited tumorigenic or
metastatic potential in vivo, whereas a second subpopu-
lation is enriched in CSCs as inferred from vigorous
anchorage-independent growth and tumor formation
and lung colonization potential in vivo. We had previ-
ously found that the non-CSC subpopulation enhances
the ability of the CSC subpopulation for metastatic dis-
semination, and produced preliminary evidence that this
activity involved, at least in part, diffusible factors secreted
by S cells [11]. In the present study, we have confirmed
and extended our original observations, including the in-
duction of epithelial-mesenchymal transition in the CSC-
enriched epithelial PC-3M subpopulation upon culture
with conditioned medium from the non-CSC PC-3S sub-
population, and the dependence of this effect on specific
signaling pathways.
We have applied a comparative proteomics approach
in an effort to identify proteins differentially secreted by
S (non-CSC) vs. M (CSC) cells as candidates to explain
the observed paracrine effects. Immunodepletion, spe-
cific transcript knockdown and complementation experi-
ments have led us to conclude that, of the secreted
proteins with the strongest differential secretion between
S and M cells, the matricellular protein SPARC, abun-
dantly secreted by S cells, explains most of the pro-
invasive effects of S conditioned medium on M cells.
Knock down of SPARC abrogated not only the pro-
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non-CSC S subpopulation on the CSC-enriched M cells,
but also the overall pro-invasive and pro-metastatic activ-
ities observed upon co-culture in vitro or co-inoculation
in vivo. Of note, conditioned medium from non-CSC S
cells required specific signaling pathways for the enhance-
ment of the invasive behavior of M cells, including PI3K,
MAPK, NF-κB and non-receptor tyrosine kinase path-
ways, which are also involved in cellular responses elicited
by SPARC [34]. The observed induction by SPARC in M
cells of the MAPK and PI3K-AKT signaling pathways fur-
ther supports the role played by these pathways in our
model. This underlines the relevance of paracrine interac-
tions between tumor cell subpopulations displaying non-
CSC and CSC properties to modulate the phenotypic out-
comes of the tumor. Other laboratories performing un-
biased secretome analyses have shown that SPARC also
mediates cooperation between tumor cell subpopulations
with different invasive potentials in ovarian and bladder
cancer models [17,35].
Although our knockdown and complementation experi-
ments strongly support that SPARC is indeed the key fac-
tor mediating invasive and metastatic cooperation in our
interacting CSC vs. non-CSC neoplastic subpopulation
model, other molecules produced by neoplastic or non-
neoplastic cells, such as PAI-1, could also participate in
this process. In this regard, we observed that knockdown
of SPARC in S cells was accompanied with a decrease in
PAI-1 expression. It is known that the expression of PAI-1
is modulated by changes in the expression levels of
SPARC [26]. Our subsequent immunodepletion experi-
ments suggest that PAI-1 may not play a major role in the
enhanced invasiveness of M cells by S-CM. However, add-
itional experiments may be required to completely rule
out the involvement of PAI-1 in the cooperative inter-
action between our tumor cell subpopulations, albeit sec-
ondary to modulation of SPARC levels.
SPARC, also known as osteonectin or BM-40, is a
matricellular glycoprotein expressed in a variety of tissues
during development and tissue repair and remodeling that
regulates extracellular matrix deposition and cell-matrix
interactions [36]. SPARC has been shown to regulate cell
proliferation, cell rounding, cell adhesion, angiogenesis,
extracellular matrix remodeling and tumorigenesis, and to
be involved in epithelial-mesenchymal transition. In can-
cer, SPARC has been reported to exert apparently con-
trasting activities [37-39], either stimulating or inhibiting
cell migration and invasion, promoting or reducing tumor
growth and metastatic dissemination, sustaining cell sur-
vival or causing apoptosis, senescence and sensitization
to genotoxic drugs. This suggests that the outcomes of
activities mediated by SPARC may be context-dependent.
Relevant variables include the source of SPARC (tumoral,
stromal, or hematopoietic cells) with differences inglycosylation or peptide fragment patterns that result
in functional differences, activities mediated by intra-
cellular vs. extracellular SPARC, or the status of path-
ways regulated by p53 or PTEN [34]. The contrasting
activities displayed by SPARC in different normal and
neoplastic cell types are reflected in its varying status
in different tumors [40]. Thus, SPARC expression is el-
evated in many tumor types, including prostate cancer
[27], and it has been found to enhance the migration
and invasiveness of prostate cancer cells [41,42]. In
contrast, other studies have reported downregulation
of SPARC in several tumor types, often in association
with promoter hypermethylation, and its expression
levels to be negatively correlated with tumor stage,
therapeutic response or patient outcome. The import-
ance of the interactions between neoplastic cells and
tumoral environment is highlighted by the associations
of stromal expression of SPARC with tumor progres-
sion and patient outcome [43].
We have found that both primary prostate cancer
samples associated with metastasis and those without
metastatic association express SPARC in their stromal
components at variable levels that do not correlate with
metastatic status. However, our immunohistochemical
analysis has revealed that only those primary tumors
associated with metastasis express significant levels of
SPARC in their epithelial tumoral components. The ori-
gin of this SPARC in the neoplastic component is sup-
ported by laser microdissection and RNA quantification
experiments that allow us to distinguish the epithelial-
tumoral vs. stromal origin of SPARC and show that SPARC
immunostaining in the epithelial tumoral component cor-
relates with the expression of relatively high mRNA levels
in the tumoral component. The observed staining pattern
was generally cytoplasmic, perinuclear or juxtamembrane
dots, but also a diffuse nuclear staining in a significant pro-
portion of cells in over half of the metastatic primary
tumor samples analyzed. A nuclear localization of SPARC
has long been noted [44,45] and, although the potential
functions of this nuclear form of SPARC are unknown, it
has been linked to cellular proliferation [44]. The observed
enhanced epithelial/stromal ratios of SPARC expression
levels in metastasis-associated primary tumors did not re-
sult in increased overall SPARC transcript levels in the
same samples or in plasma SPARC protein levels. These
observations, along with those from our in vitro and
mouse xenograft cell models, underscore the importance
of tumor-produced SPARC over that produced by stromal
cells in conferring a metastatic phenotype to prostate can-
cer tumor cells.
There is consistent experimental evidence that the extra-
cellular matrix remodeling, antiangiogenic and antiprolifer-
ative effects mediated by non-tumoral SPARC, produced
by stromal fibroblasts or endothelial or hematopoietic
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and metastasis in mouse models of lung, ovarian, bladder,
prostate or pancreas cancers [43,46-50]. Such a conclusion
is in line with a potentially more general anti-metastatic
function of tumoral stroma, as highlighted by recent ob-
servations [51,52] that are prompting a revision of prior
notions on the role of the tumor microenvironment in
modulating the metastatic behavior of cancer cells [53]. In
parallel, there is also substantial evidence that SPARC en-
dogenously produced by cancer cells favors their invasive,
survival and tumorigenic properties [24,54-62]. The rele-
vance in human tumor progression of a cell-autonomous
pro-metastatic function of SPARC is supported by its
expression by the cancerous components of metastatic
primary tumor samples of glioblastoma, melanoma and
prostate cancer, but not in samples from non-metastatic
primary tumors [18,40,55,61].
Few experimental models have simultaneously addressed
the role of both cancerous and non-cancerous SPARC in
tumor progression. A TRAMP mouse model crossed to
SPARC−/− mice [50] concluded that both cancerous and
non-cancerous SPARC exert tumor suppressor functions.
Our results, however, suggest a different perspective in
which (1) a relevant factor may be the interaction between
SPARC-producing cancerous subpopulations, which are
non-metastatic in our model (S cells), with SPARC-
responding cancerous subpopulations (M cells in our
model) to enhance the invasive and metastatic behavior of
the latter; and (2) the ratio of cancerous to non-cancerous
stromal SPARC expression levels, rather than overall tu-
moral or stromal-only expression, may be a significant de-
terminant of metastatic behavior, as suggested by our
immunohistochemical analysis and transcript quantifica-
tion of metastatic and non-metastatic primary prostate
cancer samples. A pro-metastatic function of SPARC en-
dogenously produced by neoplastic cells may be attributed
to its increased levels and a paracrine function in
metastasis-promoting neoplastic cells and possibly also to
differences in one or more properties of SPARC produced
by non-neoplastic stromal cells, as suggested by its prom-
inent nuclear localization in a significant proportion of
metastatic primary tumors. There is evidence for differen-
tial postranslational processing of SPARC in different cell
types, potentially leading to differential functions [40],
and it remains to be explored if this applies to non-
neoplastic vs. neoplastic or non-metastatic vs. meta-
static cancer cells.
In addition to our own previous observations [11], other
studies have provided examples of cooperation between
heterogeneous tumor cell subpopulations that leads to en-
hanced metastatic behaviors of tumors [8,33,63,64]. One
of these studies has identified non-cancerous fibronectin
as a key extracellular protein to support the enhanced
invasiveness prompted by cooperating neoplastic cellsubpopulations [63]. Our current study is the first to
identify a specific extracellular matrix remodeling factor
produced by a non-CSC neoplastic cell subpopulation as
responsible for instigating the invasion and metastatic be-
havior of a second subpopulation displaying CSC proper-
ties. Matricellular proteins, including osteopontin, tenascin
or SPARC, are gaining increasing attention for their roles
in shaping local or metastatic niches to either support or
prevent the growth and colonization potentials of tumor
cells [38,65,66]. The observations described here indicate
that SPARC can also participate in paracrine interactions
between tumor cell subpopulations and influence their
metastatic potential.
Conclusions
Interactions among tumor cell subpopulations with dis-
tinct phenotypes and gene programs impact the overall
behavior of a given tumor. Our analysis of interactions be-
tween clonal subpopulations displaying CSC or non-CSC
properties has led to the identification of novel paracrine
interactions among such subpopulations through the se-
cretion by a non-CSC subpopulation of the matricellular
protein SPARC, which boosts the invasive and metastatic
potentials of a CSC-enriched subpopulation. Our findings
expand the previously known functions of SPARC in
tumor-stromal interactions to include interactions among
neoplastic subpopulations that impinge upon the meta-
static behavior of tumor cells. Finally, the importance of
the production of SPARC by tumor cells, in contrast to
that produced by stromal cells, in favoring the metastatic
spread of prostate cancer cells is underscored by our
finding that SPARC is expressed by primary prostate
adenocarcinoma cells from metastatic cases, but not
from non-metastatic cases. Based on our observations,
we conclude that neoplastic-produced SPARC constitutes
a potential tumor progression biomarker and a therapeutic
target in advanced prostate cancer.
Materials and methods
Cell lines
Luciferase-bearing PC-3M and PC-3S cells were clonally
derived from the human cell line PC-3 [11]. Du-145,
CWR22v1 and LNCaP cells were obtained from the
American Type Culture Collection (Manassas, VA). Cells
were grown at 37°C in a 5% CO2 atmosphere in RPMI
1640 medium supplemented with 10% fetal bovine serum,
L-glutamine, non-essential aminoacids, sodium pyruvate,
penicillin/streptomycin (PAA Laboratories, Coelbe, Germany)
and geneticin (Santa Cruz Biotechnologies, Santa Cruz,
CA).
Spheroid formation assay
Cells (103/well) were seeded on 24-well Ultra Low Attach-
ment culture plates (Corning Costar, Cambridge, MA) in
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lose (Sigma-Aldrich, St. Louis, MO), allowed to grow for
14 days and spheroids scored by image acquisition and
spheroid area quantification with ImageJ.
In vitro invasiveness assays
Transwell-Matrigel invasion assays were performed as
described [11]. To harvest S conditioned medium (S-
CM) or M conditioned medium (M-CM), cells were cul-
tured to 70% confluence, at which time the culture
medium was replaced with fresh CD-CHO medium
(Invitrogen) supplemented with 8 mM glutamine (PAA).
After 48 h, conditioned media were collected, centri-
fuged and filtered through a 0.2 μm filter (VWR Com-
pany, Darmstadt, Germany). M cells were analyzed for
invasiveness by seeding with S-CM or M-CM (control)
on Matrigel-hyaluronic acid-coated Transwell chambers.
For co-culture experiments, M cells were loaded with
Oregon Green 488 carboxy-DFFDA-SE (Invitrogen) and
S cells with Far Red DDAO-SE (Invitrogen), by adding
25 μM of fluorophore to the cell suspensions for 30 min,
washed with PBS, and reseeded. Fluorophore-preloaded
cells were co-cultured at a 1:1 ratio on Matrigel-Transwell
units and scored for invasiveness after 24 h.
SILAC labeling and sample preparation
M and S cells were cultured in L-lysine and L-arginine-
depleted RPMI (Thermo Scientific, Hudson, NH) sup-
plemented with 10% dialyzed FBS, antibiotics (PAA),
and either 0.1 mg/mL 12C6- (M) or 0.1 mg/mL
13C6- (S),
L-lysine and L-arginine (Thermo). The medium was re-
placed every 2 days, and cells routinely passaged at 80-
90% confluence. After 14 days, cells were cultured for 2
days in light (M) or heavy (S) labeled medium without
FBS, conditioned mediums collected, centrifuged, fil-
tered through a 0.2 μm filter (VWR) and concentrated
using Amicon centrifugal filter devices with a 3-kDa mo-
lecular weight cut-off (Millipore, Billerica, MA). Protein
content was quantified (Bradford RcDc protein assay;
BioRad, Hercules, CA) and 15 μg of each sample were
mixed, diluted in 50 mM ammonium bicarbonate and con-
centrated using an Amicon centrifugal filter device with a
10-kDa molecular weight cut-off (Millipore). The <10 kDa
fraction was evaporated to dryness, resuspended in 8 M
urea, 50 mM ammonium bicarbonate, reduced with
50 mM dithiothreitol, alkylated with 125 mM iodoaceta-
mide, digested with trypsin and analysed by LC-MS.
The >10 kDa fraction was resuspended in loading buffer
and subjected to electrophoresis on a 12.5% SDS-
polyacrylamide gel.
Mass spectrometry analysis
After SDS-PAGE and Coomassie blue staining, lanes
were split into 10 slices, digested with modified porcinetrypsin (Promega, Madison, WI), dried, extracted with
formic acid solution and analyzed on an Esquire Ultra
IT mass spectrometer (Bruker, Bremen, Germany)
coupled to a nano-HPLC system (Ultimate; LC Packings,
Amsterdam, The Netherlands). Peptide mixtures were
concentrated on a 300 mm i.d., 1 mm PepMap nano-
trapping column and loaded onto a 75 mm i.d., 15 cm
PepMap nanoseparation column (LC Packings). Pep-
tides were eluted by an acetonitrile gradient (0–60% B
in 150 min, where B is 80% acetonitrile, 0.1% formic
acid in water; flow rate ca. 300 nL/min) through a Pico-
Tip emitter nanospray needle (New-Objective, Woburn,
MA) onto the nanospray ionization source of the IT
mass spectrometer. MS/MS fragmentation (1.9 s, 100–
2800 m/z) was performed on three of the most intense
ions, as determined from a 1.2 s MS survey scan (310–
1500 m/z), using a dynamic exclusion time of 1.2 min
for precursor selection and excluding single-charged
ions.
Protein identification and data analysis
Protein identification and quantification was performed
using Protein Scape 2.1 and WARP-LC 1.2 (Bruker).
Proteins were identified using Mascot (Matrix Science,
London, UK) on the SwissProt human protein database.
MS/MS spectra were searched with a 1.5 Da precursor
mass tolerance, 0.5 Da fragment tolerance, 1 missed
cleavage maximum trypsin specificity, cysteine carba-
midomethylation set as fixed modification and methio-
nine oxidation and the N-terminal and Lys and Arg
SILAC labels as variable modifications. Positive identifi-
cation criterion was set as an individual Mascot score
for each peptide MS/MS spectrum above the homology
threshold score. False positive rates for Mascot protein
identification were measured by searching a randomized
decoy database [67], and estimated to be under 4%. For
relative protein quantification, H/L ratios were calcu-
lated averaging the measured H/L ratio for the observed
peptides, after discarding outliers. For selected proteins
of interest, quantitative data obtained from the automated
Protein Scape analysis were manually curated. For further
protein analysis, UniProtKB (http://www.uniprot.org)
and GeneCards databases (http://www.genecards.org) were
used.
Western blotting
Samples were resuspended in Laemmli buffer (100 mM
dithiothreitol, 50 mM TrisCl pH 6.8, 2% SDS, 0.1%
bromophenol blue, 10% glycerol) and boiled for 5 min.
Equal amounts of protein were resolved by SDS-PAGE.
After electrophoresis, proteins were transferred onto
fluorescent-PVDF membranes (Immobilon-FL, Millipore)
for 2–4 h. Blots were washed, blocked with blocking buf-
fer (Odyssey, LI-COR), incubated overnight with primary
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(0.1%) (1:1), washed in PBS-T (or TBS-T) and incubated
for 1 h with fluorescent secondary antibody IRDye (LI-COR
Biosciences, Lincoln, NE). After final washes in PBS-T
(or TBS-T), the membranes were scanned using the
Odyssey Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE). Antibodies to the following antigens were
used: SPARC (1:200) (H-90, Santa Cruz), PAI-1 (1:200)
(C-9, Santa Cruz), AKT1 (1:100) (C-20, Santa Cruz),
phospho-AKT1 (1:100) (pSer473, Santa Cruz), ERK1/2
(1:200) (H-72, Santa Cruz), phospho-ERK1/2 (1:100)
(pThr177/pThr160, Santa Cruz), ILK (1:100) (E-2, Santa
Cruz), phospho-ILK (1:100) (pThr173, Santa Cruz) and
β-tubulin (1:2,000) (Sigma).
Lentiviral shRNA production and transduction
pLKO.1-Puro plasmids for control (shC002) and
SPARC-targeting shRNAs TRCN0000008709 (sh8709)
and TRCN0000008711 (sh8711) were from Sigma-Aldrich.
Doxycycline-inducible SPARC-targeting V2THS_153399
(sh3399) was from Thermo. Each of these plasmids
was co-transfected in HEK293T cells with pVSVG and
pCMVΔR8.91 (Clontech, Mountain View, CA) using
X-tremeGENE9 (Roche). Supernatants were collected
for the following 48 h and filtered through 0.45 μm
methylcellulose filters (Millipore). Viral particles were
concentrated by ultracentrifugation on 20% sucrose
gradients. Target cells were transduced in the presence
of polybrene (8 μg/mL; Sigma-Aldrich), and selected
with 1 μg/mL puromycin (Sigma-Aldrich) for 7 days.
Production and purification of recombinant human
SPARC
HEK 293T cells bearing integrated copies of a human
SPARC expression vector [68] were grown in DMEM
supplemented with 10% FBS and 3 μg/mL puromycin.
Confluent cells were grown in serum- and puromycin-
free medium and conditioned medium harvested every 2
or 3 days for 7–8 harvests and concentrated 10-fold on
30,000 Da cut-off Amicon centrifugal filter devices
(Millipore) with simultaneous exchange into starting
buffer (20 mM MOPS, 200 mM LiCl, pH 6.5). Concen-
trates were bound to a Maxi Anion (Q) Spin Column
(Thermo) equilibrated with starting buffer and eluted
with 30% elution buffer (20 mM MOPS, 400 mM LiCl,
pH 6.5). SPARC-containing fractions, monitored by
SDS-PAGE, were concentrated and dialyzed against
Hank’s balanced salt solution (HBSS).
Immunodepletion experiments
S-CM was obtained as described above and subjected
to immunoprecipitation using 2 μg/mL rabbit anti-SPARC
(H-90, Santa Cruz) or anti-PAI-1 (C-9, Santa Cruz)
plus pre-washed protein G-Sepharose (GE Healthcare,Buckinghamsire, UK) at 4°C for 2 h. Subsequently,
samples were centrifuged and supernatants collected
and used in invasiveness assays. Pelleted beads were
washed three times with PBS and resuspended in
Laemmli buffer. Aliquots from supernatant and resus-
pended pelleted beads were processed for Western
blotting analysis as above.
Orthotopic prostate model and bioluminescence imaging
(BLI)
M and S.sh3399 cells were transduced with the pRRL-
Luc-IRES-EGFP lentiviral vector [11] for the constitutive
expression of the firefly luciferase gene to generate M.
Fluc and S.Fluc.sh3399 cells, respectively. M.Fluc cells
(1 × 105), or a mix of M.Fluc (1 × 105) with S.Fluc.sh3399
(1 × 105) cells, pretreated or not in vitro with doxycycline
(1 μg/mL; Sigma-Aldrich), resuspended in 30 μL sterile
PBS, were inoculated into the dorsal prostates of 6-week-
old SCID-Beige mice. Doxycycline (1 mg/mL) was admin-
istered ad libitum in drinking water containing 25 mg/mL
sucrose (Sigma-Aldrich) to induce the expression of
shSPARC. BLI was performed with the IVIS Spectrum
Imaging System (Perkin Elmer Life Science, Boston,
MA), and images and measurements were acquired and
analyzed using the Living Image 4.3.1 software (Perkin
Elmer). For in vivo BLI, animals were anesthetized with 1-
3% isoflurane (Abbott Laboratories, IL) and injected i.p.
with 150 mg/kg of D-luciferin (Promega) in sterile PBS.
For ex vivo BLI, mice were injected i.p. with 150 mg/kg D-
luciferin prior to euthanasia. Immediately postmortem, or-
gans of interest were placed individually into separate
wells with 300 μg/mL D-luciferin, imaged and quantified
as above. These experiments were performed at the
CIBER-BBN In Vivo Experimental Platform.
RNA isolation, reverse transcription and real-time RT-PCR
RNA purification and reverse transcription were per-
formed as described [11]. Real-time quantitative PCR as-
says were performed on a LightCycler 480 instrument
(Roche) and analyzed with the LightCycler 480 Software
release 1.5.0. The Universal Probe Library system (UPL)
(Roche) was used to quantify transcripts. Probes and se-
quences are shown in Additional file 2: Table S2. RN18S1
amplification levels were used as an internal reference,
and relative transcript quantification determined by the
ΔΔCp method. Tissue samples were procured through the
Hospital Clínic-IDIBAPS Biobank, a Generalitat de
Catalunya authorized biobank registered at the Instituto
de Salud Carlos III, and thus sample collection and pro-
cessing fulfilled all ethical and legal requirements.
Tissue microdissection and transcript quantification
Eight formalin-fixed paraffine-embedded samples were
used for laser microdissection, 4 from non-metastatic
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from each sample were mounted onto plastic membrane
slides (Leica Microsystems, Germany), stained with
hematoxylin-eosin, air dried and stored at −80°C until
use. Laser microdissection was performed with the Leica
LMD7000 System (Leica). Approximately 3 mm2 of either
tumoral epithelium or stroma were collected separately
for each sample. RNA isolation was performed with the
RNeasy FFPE Kit (Qiagen) and reverse transcribed with
the High-Capacity cDNA Reverse Transcription Kit (Life
Technologies). cDNA was preamplified (14 cycles) with
the TaqMan PreAmp Master Mix (Life Technologies).
SPARC transcript levels were quantified using a TaqMan
assay (Hs00234160_m1) and normalized to β-2 micro-
globulin (B2M) transcript levels (assay Hs00984230_m1).
Real-time PCR assays were performed and analyzed as
described above.Immunohistochemistry
A total of 30 samples were used for immunohistochemical
detection of SPARC protein, 14 from non-metastatic and
16 from metastatic cases. Two μm thick sections were
mounted on xylaned glass slides (DAKO, Glostrup,
Denmark) and processed for antigen retrieval in citrate
buffer pH 6 for 20 minutes, incubated for 1 h with
rabbit-anti-SPARC (1:300) (H-90, Santa Cruz) and reac-
tions revealed with the Bond Polymer Refine Detection
System (Leica, Wetzlar, Germany). The staining was
scored as the percentage of positive cells with null, weak,
moderate or strong intensities, scoring separately the
epithelial and stromal compartments of each sample.
Images were captured with an Olympus BX-51 micro-
scope equipped with an Olympus DP70 camera.Immunocytochemistry
Cells were seeded on sterile round glass coverslips,
allowed to attach for 24 to 48 h, washed with PBS, fixed
with cold 4% paraformaldehyde for 20 min, permeabilized
with 1% Triton X-100 in PBS, blocked for 30 min with
blocking buffer (3% BSA, 1% Triton X-100 in PBS), incu-
bated with primary antibody (anti-SPARC, 1:50 in block-
ing buffer) for 2 h at room temperature, washed 3× with
blocking buffer, and incubated for 30 min with Alexa
Fluor 488-conjugated rabbit-anti-mouse antibodies (Life
Technologies; 1:1,000 in blocking buffer), Alexa Fluor
555-conjugated phalloidin (Life Technologies; 1:10,000)
and 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochlor-
ide, 4′,6-Diamidino-2-phenylindole (DAPI) dihydrochloride
(Sigma; 0.1 μg/mL). After washes, samples were mounted
on glass slides with Mowiol 18–88 (Sigma) and visualized
under a Leica SP5 confocal microscope (Leica, Wetzlar,
Germany).Plasma SPARC quantification by ELISA (Enzyme-Linked
ImmunoSorbent Assay)
Plasma samples were collected from 4 healthy controls
(blood PSA <4 ng/mL) and 10 non-metastatic and 14
metastatic prostate cancer patients, using EDTA as anti-
coagulant. Blood from patients was extracted prior to
prostatectomy. No patients or controls were under sys-
temic treatment at the time of blood extraction. Quanti-
fication of SPARC protein levels was performed using
Quantikine ELISA Human SPARC Immunoassay (R&D
Systems, Abingdon, UK). Tissue and blood samples were
procured through the Hospital Clínic-IDIBAPS Biobank,
a Generalitat de Catalunya authorized biobank registered
at the Instituto de Salud Carlos III, and thus sample
collection and processing fulfilled all ethical and legal
requirements.
Statistical analysis
A Student’s t-test was applied to two-way comparisons
of data sets from in vitro experiments. A non-parametric
Mann–Whitney test was applied to SPARC level determi-
nations in tissues and blood and for bioluminescent data
from xenograft experiments. The significance threshold
was established at P < 0.05, and significance levels were sche-
matically assigned * (0.01 ≤P < 0.05), ** (0.001 ≤P <0.01) or
*** (P < 0.001).
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